![]() ![]() All dose levels of mRNA-1777 (V171) were generally well tolerated and no serious adverse events related to the vaccine were reported. Primary objectives were safety and tolerability and secondary objectives included humoral and cell-mediated immunogenicity. Seventy-two younger adults were randomized and administered 25, 100, or 200 µg mRNA-1777 (V171) or placebo, and 107 older adults were randomized and administered 25, 100, 200 or 300 µg mRNA-1777 (V171) or placebo. For each dose level, three sentinel participants were administered open-label mRNA-1777 (V171). Participants received mRNA-1777 (V171) or placebo as a single intramuscular dose. The study was conducted in healthy younger adults (ages ≥18 and ≤49 years) and healthy older adults (ages ≥60 and ≤79 years). In this randomized, partially double-blind, placebo-controlled, phase 1 dose-escalation study, we evaluated the safety, tolerability and immunogenicity of an investigational messenger ribonucleic acid (mRNA) vaccine encoding the RSV fusion protein (F) stabilized in the prefusion conformation. A safe and effective RSV vaccine for older adults represents a serious unmet medical need due to higher morbidity and mortality in this age group. The risk for severe RSV infection is highest in infants and older adults. ![]() Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that can be severe and sometimes fatal. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |